Keyphrases
Allelic Imbalance
12%
Autoimmune Lymphoproliferative Syndrome
5%
BRCAness
5%
Chemotherapy
12%
Childhood Cancer
8%
Clinical Characteristics
5%
Constitutional Mismatch Repair Deficiency (CMMRD)
7%
Etoposide
6%
Event-free Survival
6%
Ewing Sarcoma Family of Tumors
5%
Favorable Outcome
6%
Gene Expression
7%
Gene Fusion
6%
Gene Signature
5%
Genetic Modification
12%
Genomic Instability
5%
Germ Cells
10%
Germany
7%
High Risk
7%
High-grade Osteosarcoma
9%
Immune Thrombocytopenia
5%
Loss of Heterozygosity
7%
Lymphoproliferative Disorders
5%
Malignancy
6%
Metastasis
8%
MicroRNA
8%
Microsatellite Instability-high (MSI-H)
8%
MiR-17-92 Cluster
5%
Multiple Myeloma
5%
Oncogene
6%
Osteosarcoma
100%
Osteosarcoma Cell Lines
6%
Osteosarcoma Cells
8%
Overexpression
6%
Pediatric
11%
Pediatric Cancer Patients
5%
Pediatric Oncology
9%
Precision Oncology
5%
Prognostic Factors
6%
Promoter Genes
5%
Radiation Effects
6%
Randomized Controlled Trial
5%
Rhabdomyosarcoma
10%
Sickle Cell Disease
5%
Targeted Therapy
5%
Telehealth
5%
Tumor
32%
Tumor Protein p53 (TP53)
11%
Tumor Suppressor Gene
5%
Whole-body MRI
5%
Biochemistry, Genetics and Molecular Biology
Allele
5%
Allelic Imbalance
13%
Alpha Radiation
5%
Carcinogenesis
13%
Chromothripsis
7%
DNA Mismatch Repair
9%
Ewing Sarcoma
5%
Gene Expression Profiling
8%
Gene Fusion
7%
Gene Mutation
11%
Genetics
19%
Genome Instability
8%
Genomics
19%
Genotyping
5%
Germ Cell
13%
Germline
13%
Karyotype
7%
Long Term Survival
6%
Loss of Heterozygosity
7%
Messenger RNA
5%
MicroRNA
11%
Microsatellite Instability
8%
Myeloid
5%
Oncogene
5%
P53
7%
Pan-cancer
5%
Programmed Cell Death
6%
Promoter Region
10%
Signal Transduction
5%
Single-Nucleotide Polymorphism
7%
Transcription Factors
7%
Tumor Suppressor Gene
6%
Medicine and Dentistry
Cancer
10%
Cancer Susceptibility
6%
Childhood Cancer
12%
Diseases
14%
Epstein Barr Virus
5%
Etoposide
6%
Event Free Survival
6%
Ewing Sarcoma
7%
Ganglioneuroblastoma
8%
Metastatic Carcinoma
12%
Neoplasm
32%
Osteosarcoma
51%
Pediatric Cancer
7%
Pediatrics
19%
Personalized Medicine
5%
Precision Oncology
5%
Progression Free Survival
5%
Randomized Controlled Trial
5%
Receptor
5%
Recurrent Disease
8%
Rhabdomyosarcoma
8%
Stem Cell
6%
T Cell
8%
Targeted Therapy
7%
Telehealth
5%
